The data on discovery output versus phase three reach is quite striking. It makes sense that a disciplined development infrastructure is needed to bridge that gap. The fund seems well positioned to address this specific market need.
Haven't used One in Eight · The Prostate Cancer Fund yet?
Ask Trustburn
Questions about One in Eight · The Prostate Cancer Fund
What is One in Eight · The Prostate Cancer Fund?
One in Eight is a $100 million venture fund focused on prostate and related cancers, built by leaders in prostate cancer research. It seeds and funds companies aiming to eliminate these cancers as a cause of death and suffering. The fund plans to invest in 15 to 20 early-stage companies from seed to Series A stages. Its portfolio is anchored in prostate cancer and extends to cross-cancer opportunities where the underlying science applies.
Who are the key people behind the fund's scientific direction?
The fund is led by five founding key opinion leaders whose networks are associated with approximately half of approved prostate cancer drugs. These experts bring direct clinical and development experience across the AR-pathway, PARP, hormonal, and radiopharma classes. Their collective expertise includes drug-approval studies they led for Rubraca, Pluvicto, Xofigo, Nubeqa, Orgovyx, Zytiga, and Xtandi.
What specific problem does the fund aim to solve in cancer development?
The fund operates out of the United States and targets companies working to eliminate prostate and related cancers as a cause of death and suffering. It focuses on building a more intelligent, compressed development engine that sorts through the morass of available molecules and designs clinical programs. This infrastructure aims to manage burn and decide which candidates deserve a patient.
What stage of companies does the fund primarily target for investment?
The fund targets companies at the seed to Series A stages, with a plan to invest in 15 to 20 early-stage companies. It anchors its portfolio in prostate cancer while also extending to cross-cancer opportunities where the underlying science applies. The fund seeks to fill the structural gap between existing molecules and the disciplined development infrastructure needed to reach patients.
How does the fund integrate clinical trial execution into its strategy?
The fund's clinical engine has been operational since 2005 through the Prostate Cancer Clinical Trials Consortium (PCCTC). This consortium runs early-phase PCa trials at scale and has accrued 17,780 patients across 332 studies since 2005. Portfolio companies gain access to discounted trial execution in exchange for warrants and portfolio terms.
What market trends does the fund base its investment thesis on?
The fund's thesis relies on a flywheel model where discovery output has increased roughly 6× since 2005, with China alone now accounting for approximately one-third of global IND filings. However, fewer than 1 in 10 candidates entering clinical trials reach pivotal trials, creating a bottleneck in development. The fund aims to address this by building a smarter development engine.
What core principles guide the fund's operations according to its own website?
The fund's website states that it is built by leaders in prostate cancer research to seed and fund companies aiming to eliminate prostate and related cancers as a cause of death and suffering. It describes itself as an NXP fund with a focus on persistent demand and multiple shapes of cancer. The fund positions itself as a cure-focused initiative anchored in prostate cancer.
What level of experience do the fund's advisors bring to deal evaluation?
The fund's website mentions that it has a collective of 100+ years across drug approval, clinical leadership, and pharma corporate development. This experience is applied to every deal to ensure rigorous evaluation of potential investments. The fund's operational thread connects the fund, founder, and clinical engine to execute its mission.
What specific gap in the cancer development landscape does the fund aim to fill?
The fund's website states that it has a persistent buyer demand and molecules exist, but the missing piece is the disciplined development infrastructure between them. It notes that the demand renews every cycle and that the opportunity lies in building a more intelligent, compressed development engine. The fund aims to fill this structural gap rather than addressing a temporary trend.
How is One in Eight · The Prostate Cancer Fund rated on Trustburn?
On Trustburn, One in Eight · The Prostate Cancer Fund has a rating of 3.8 out of 5 based on 5 reviews.
Post your question publicly — other visitors, and whoever manages this page, can answer. It will be visible on this page.
Want to hear about this company again? Follow it and we’ll email you when a new review appears.
Based on reviews, listing data and the company's website. Verify anything important with the company directly.
5 Reviews
The discounted trial execution is a nice perk, but the exact cost implications for portfolio companies are not detailed. It is unclear if the warrants provide sufficient value to offset any hidden fees.
The integration of the clinical engine with the fund is a clever way to de-risk development. However, the reliance on warrants and portfolio terms for discounted execution might complicate standard deal structures. It is a sophisticated model, but the specific mechanics of how these clinical partnerships translate to commercial outcomes are not entirely clear from the available information.
What stands out is how One in Eight Ventures bridges the gap between discovery explosion and clinical development. The fact that ~50% of approved prostate cancer drugs trace back to their founding KOL network is remarkable. It feels like a truly expert-led approach rather than just being informed by experts. The flywheel model connecting sourcing, investment, and clinical execution is compelling. Portfolio companies get direct access to the Prostate Cancer Clinical Trials Consortium, which has accrued nearly eighteen thousand patients. That operational thread connecting the fund to discounted trial execution is a huge value add. It seems like they are solving a real structural gap in how molecules reach patients. The focus on eliminating prostate cancer as a cause of death gives the mission a clear, cure-oriented direction. I am very impressed by the depth of experience across AR-pathway and radiopharma classes.
The connection between the fund and the clinical trials consortium looks very practical. Having direct access to discounted trial execution seems like a genuine advantage for early-stage companies navigating development hurdles.
Questions & Answers
No questions yet — be the first to ask.
Sign in to post
Your text is saved — you'll come right back to post.
or with email
Don't have an account? Create one
News & Press
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
About One in Eight · The Prostate Cancer Fund
One in Eight is a $100 million venture fund focused on prostate and related cancers. It was built by leaders in prostate cancer research and seeds and funds companies working to eliminate those cancers as a cause of death and suffering. The fund plans to invest in 15 to 20 early-stage companies, from seed to Series A stages. Its portfolio is anchored in prostate cancer and extends to cross-cancer opportunities where the underlying science applies. The fund is led by five founding key opinion leaders whose networks are associated with approximately half of approved prostate cancer drugs.
- Website
- 1in8.vc
- [email protected]
- Categories
- Investment management
People also looked at
1inow5 Reviews
One Is No Fun4 Reviews
Invexa Technologies4 Reviews
Tienda en línea de Tiendas Tejedor MX5 Reviews
Alhikma Advanced Rapid Trading Est0 Reviews